News
1h
Zacks Investment Research on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...
Pedersen, Global Head of Pharma Technical Operations at Roche, shares how she has navigated the various pivots in her career, ...
VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 25, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results